ABO血液型不適合移植の新戦略―2007―

出版社： 日本医学館
著者：
発行日： 2007-07-24
分野： 臨床医学：外科  >  移植/人工臓器
ISBN： 9784890446339
電子書籍版： 2007-07-24 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,750 円(税込)

購入する

商品紹介

今回はABO-blood-group-related-antigens（ＡＢＯ血液型関連抗原）に起因するacute AMRを分類することにより、移植前の脱感作療法がこの移植にとって特に重要な役割を果たしていることを紹介する。（序より）

目次

  • ABO血液型不適合移植の新戦略―2007―

    ―目次―

    第13回日本ABO血液型不適合移植研究会
    主題：ABO血液型不適合臓器移植における免疫抑制療法

    特別講演
    　ABO血液不適合腎移植における最近の知見

    統計
    　1．わが国におけるABO血液型不適合腎移植の現況報告2006
    　2．ABO血液型不適合生体肝移植2006年集計報告

    REPORT　
    　坑A坑B抗体価測定における施設間較差の検討（第4報）

    肝移植
    　1．Immunotoxinを用いた新しい坑血液型抗体産生B細胞の
    　　　特異的排除法とABO血液型不適合肝・腎移植への
    　　　応用の可能性
    　2．当院外来管理中の小児ABO血液型不適合肝移植症例の検討
    　3．当センターにおける成人ABO血液型不適合生態部分肝移植
    　　　12例の検討

    腎移植
    　1．ABO血液型不適合腎移植における坑ドナー血液型抗体値の
    　　　変動と急性拒絶反応発生率の検討
    　2．ABO血液型不適合腎移植における免疫抑制療法の変遷と成績
    　3．MMF術前4週間投与、少量リツキシマブ、非脾摘で実施した
    　　　超高齢夫婦間ABO血液型不適合移植
    　4．ABO血液型不適合生体腎移植の免疫抑制療法

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第13回日本ABO血液型不適合移植研究会 主題 : ABO血液型不適合臓器移植における免疫抑制療法

P.18 掲載の参考文献
1) 高橋公太: わが国のABO血液型不適合腎移植の統計 -第10回アンケート報告. 今日の移植 19:1-8, 2006.
 
2) Tyden G, Kumlien G, Genberg H et al.: The Stockholm experience with ABO-incompatible kidney transplantations without splenectomy. Xenotransplant 13:105-107, 2006.
 
3) Tyden G: Cost effectiveness of ABO-incompatible kidney transplantations. Transplantation 82:166-167, 2006.
PubMed
4) Montgomery RA, Simpkins CE, Segev DL: New options for patients with donor incompatibilities. Transplantation 82:164-165, 2006.
PubMed
5) Takahashi K: A case of rebound following pretransplant antibody removal, with subsequent graft loss due to humoral rejection. ABO-incompatible kidney transplantation. Elsevier Science, Amsterdam, 2001, p116-119.
 
6) Takahashi K: If graft loss occurs. Accommodation in ABO-incompatible kidney transplantation. Elsevier, Amsterdam, 2004, p177-181.
 
7) Takahashi K: A case of acute humoral rejection triggered by bacterial infection. ABO-incompatible kidney transplantation. Elsevier Science, Amsterdam, 2001, p124-128.
 
8) 高橋公太, 田中紘一・編: ABO血液型不適合移植の新戦略2001. 日本医学館, 東京2001, p1-170.
 
9) 高橋公太, 田中紘一・編: ABO血液型不適合移植の新戦略2002. 日本医学館, 東京, 2002, p1-144.
 
10) Takahashi K: Accommodation in ABO-incompatible kidney transplantation: Why do kidney grafts survive? Transplant Proc(Suppl 2S):193-196, 2004.
 
11) Takahashi K: Accommodation in ABO-incompatible kidney transplantation. Elsevier, Amsterdam, 2004, 1-209.
 
12) Takahashi K: A new concept of accommodation in ABO-incompatible kidney transplantation. Clin Transplant 19(Suppl 14):76-85, 2005.
 
13) Takahashi K, Saito K, The Japanese ABO-incompatible Kidney Transplantation Committee: Present status of ABO-incompatible kidney transplantation in Japan. Xenotransplant 13:118-112, 2006.
 
14) Saito K, Nakagawa Y, Takahashi K et al.: Pinpoint targeted immunosuppression; Anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy. Xenotransplant 13:111-117, 2006.
 
15) Takahashi K: A new immunosuppressive therapy in ABO-incompatible kidney transplantation based on a new concept of accommodation. ABO-incompatible Organ Transplantation from Japan. (ed. Takahashi K), Elsevier, Amsterdam, 2006, p71-87.
 
16) Morris PJ, Monaco AP: Book review. Accommodation in ABO-incompatible kidney transplantation. Transplantation 81:1069, 2006.
 
17) Takahashi K: Blood group antigens and their antibodies. ABO-incompatible kidney transplantation. Elsevier Science, Amsterdam, 2001, p13-19.
 
18) Takahashi K: Immunosuppressive therapy. Accommodation in ABO-incompatible kidney transplantation. Elsevier, Amsterdam, 2004, p67-68.
 
19) Takahashi K: New strategy for immunosuppression. Accommodation in ABO-incompatible kidney transplantation. Elsevier, Amsterdam, 2004, p87-99.
 
20) 高橋公太: ABO血液型不適合腎移植における新しい知見-ABO血液型関連抗原による急性抗体関連型拒絶反応の分類-. 移植 41:243-254, 2006.
Medical*Online
21) 高橋公太: ABO血液型不適合腎移植とAccommodation. Urology View 3:77-83, 2005.
 
22) 高橋公太: ABO血液型不適合腎移植における免疫学的順応のメカニズム. 泌尿器外科 18:287-293, 2005.
Medical*Online
23) 高橋公太: ABO血液型不適合臓器移植における免疫学的順応のメカニズムとその誘導. ABO血液型不適合移植の新戦略2005. (高橋公太・田中紘一・編), 日本医学館, 東京, 2005, p3-31.
 
24) Nishi S, Hasegawa S, Takahashi K et al.: The safety measures for double filtration plasma aphereis (DFPP) before ABO incompatible kidney transplantation. ABO-incompatible Organ Transplantation from Japan. (ed. Takahashi K) Elsevier, Amsterdam, 2006, p91-95.
 
25) Takahashi K, Saito K, Takahara S et al.: Excellent longterm outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 4:1089-1096, 2004.
 
26) Rydlerg L, Bengtsson A, Nilsson K et al.: In vitro assessment of a new ABO immunosorbent with synthetic carbohydrates attached to sepharose. Transplant Int 17:666-672, 2005.
 
27) Tyden G, Kumlien G, Fehrman I: Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 76:730-743, 2003.
PubMed
28) Tyden G, Kumilien G, Genberg H et al.: ABO incompatile kidney transplantation without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 5:145-148, 2005.
PubMed
29) Donauer J, Wilpert J, Geyer M et al.: ABO-incompatible kidney transplantation　using　antigen-specific immunoadsorbtion and rituximab:a single center experience. Xenotransplant 13:108-110, 2006.
 
30) Norden G, Briggs D, Rydberg L et al.: ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment. Xenotransplant 13:148-153, 2006.
 
31) 高橋公太: ABO血液型不適合腎移植における免疫学的順応とそれに基づいた免疫抑制療法の新戦略. シクロスポリン学術国際シンポジウム編, 免疫の進化. 医薬ジャーナル社, 大阪, 2006, p21-32.
 
32) Takahashi K: Timing of the start of immunosuppressive therapy(duration of desensitization therapy). Accommodation in ABO-incompatible kidney transplantation. Elsevier, Amsterdam, 2004, p94-95.
 
33) Takahashi K:Effects and complications of splenectomy. Accommodation in ABO-incompatible kidney transplantation. Elsevier, Amsterdam, 2004, p81-83.
 
34) Takahashi K:A review of humoral rejection in ABO-incompatible kidney transplantation with local (intrarenal) DIC as the underlying condition. Acta Med Biol 45:95-102, 1997.
 
P.35 掲載の参考文献
1) Takahashi K, Saito K, Tanabe K et al.: Multicenter cooperative study group :First report of a seven-year survey on ABO-incompatible kidney transplantation in japan. Clin Exp Nephrol 5:119-125, 2001.
 
2) Takahashi K, Saito K, Takahara S et al.: Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 4:1089-1096, 2004.
PubMed
3) Takahashi K, Saito K, The Japanese ABO-incompatible Kidney Transplantation Committee: Present status of ABO-incompatible kidney transplantation in Japan. Xenotransplant 13:118-112, 2006.
 
4) Alexandre GPJ, Squifflet JP, Bruyere MDE et al.: Splenec-tomy as a prerequisite for human ABO-incompatible renal transplantation. Transplant Proc 17:138-143, 1985.
 
5) Aranda JM, Scornik JC, Norman SJ et al.: Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection:acase report. Transplantation 73:907-910, 2002.
 
6) Sawada T, Fuchinoue S, Teraoka S:Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 74:1207-1210, 2002.
 
7) Tyden G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 76:730-743, 2003.
PubMed
8) Saito K, Nakagawa Y, Takahashi K et al.: Pinpoint targeted immunosuppression; Anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy. Xenotransplant 13:111-117, 2006.
 
9) Takahashi K: A new immunosuppressive therapy in ABO-incompatible kidney transplantation based on a new concept of accommodation ABO-incompatible Organ Transplantation from Japan. (ed. Takahashi K), Elsevier, Amsterdam, 2006, p73-87.
 
10) Takahashi K: Timing of the start of immunosuppressive therapy(duration of desensitization therapy). Accommodation in ABO-incompatible Kidney Transplantation. (ed. Takahashi K), Elsevier, Amsterdam, 2004, p94-95.
 
11) Mannami M, Mitsuhata N: Improved outcomes after ABO-incompatible living-donor kidney transplantation after 4 weeks of treatment with mycophenolate mofetil. Transplantation 79:1756-1758, 2005.
PubMed
P.52 掲載の参考文献
1) Zhou W et al.: NOD/SCID mice engrafted with human peripheral blood lymphocytes can be a model for investigating B cells responding to blood group A carbohydrate determinant. Transpl Immunol 12:9-18, 2003.
PubMed
2) Tanaka Y et al.: Enzyme-linked immunospot assay for detecting cells secreting antibodies against human blood group A epitopes. Transplant Proc 35 :555-556, 2003.
PubMed
3) Venkataraman L et al.: Cyclosporin-A sensitive induction of NF-AT in murine B cells. Immunity 1:189-196, 1994.
PubMed
4) Berland R et al.: Normal B-1a cell development requires B cell-intrinsic NFATc 1 activity. PNAS 100:13459-13464, 2003.
PubMed
5) Tanemura M et al.: Elimination of anti-Gal B cells by alpha-Gal ricin. Transplantation 73:1859-1868, 2002
 
P.58 掲載の参考文献
1) 猪股裕紀洋, 江川裕人:ABO不適合肝移植と患児年齢. 小児外科 33:945-950, 2001.
 
2) Ettnger R, Sarwal MM: Mycophenolate mofetil in pediatric renal transplantation. Transplantation 8 :S201-S210, 2005.
 
3) 光畑直喜, 伊藤誠一, 藤田竜二・他: MMF術前4週間投与法と少量リツキシマブの応用. ABO血液型不適合移植の新戦略2006. (高橋公太, 田中紘一・編), 日本医学館, 東京, 2006, p54-59.
 
4) Tanabe K, Tokumoto T, Ishida H et al.: Excellent outcome of ABO-incompatible living kidney transplantation under pretransplantation immunosupPression with tacrolimus, mycophenolate mofetil, and steroid. Transplant Proc 36:2175-2177, 2004.
PubMed
5) Allison AC, Eugui EM: Mechanisms of action of micophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 8:S181-S190, 2005.
 
6) 近本裕子, 服部元史, 伊藤克己:交換輸血:小児急性血液浄化療法マニュアル. (伊藤克己・監), 医学図書出版, 東京, 2002, p104-111.
 
P.63 掲載の参考文献
1) Tanabe M, Shimazu M, Wakabayashi G: Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation:Transplantation 73:1959-1961, 2002.
PubMed
2) 江川裕人: ABO血液型不適合生体肝移植全国集計 2004. ABO血液型不適合移植の新戦略2005. (高橋公太, 田中紘一・編), 日本医学館, 東京, 2005, p80-83.
 
3) 松野直徒, 中村有紀, 濱耕一郎・他: 成人間ABO血液型不適合生体腎および肝移植の実際. ABO血液型不適合移植の新戦略2006. (高橋公太, 田中紘一・編), 日本医学館, 東京, 2006, p24-29.
 
P.68 掲載の参考文献
1) Shimmura H, Tanabe K, Ishida H et al.: Lack of correlation between results of ABO-incompatible living kidney transplantation and anti-ABO blood type antibody titers under our current immunosuppression. Transplantation 80(7):985-988, 2005.
PubMed
2) Ishida H, Koyama I, Sawada T et al.: Anti-AB titer changes in patients with ABO incompatibility after living related kidney transplantation. Transplantation 70(4):681-685, 2000.
PubMed
3) Tojimbara T, Nakajima I, Sato S et al.: Result of kidney transplantation in patients receiving MMF-or MMF and basiliximab-containing immunosuppression. Transplantation Proceedings 36:2087-2089, 2004.
PubMed
4) Ando T, Tojimbara T, Sato S et al.: Efficacy of basiliximab induction therapy in ABO-incompaible kidney transplantation:arapid steroid withdrawal protocol. Transplantation Proceedings 36:2182-2183, 2004.
 
5) Sheashaa H, Bakr M, Ismail A et al.: Long-term evaluation of basiliximab induction therapy in live donor kidney transplantation:a five-year prospective randomized study. American Journal of Nephrol 25(3):221-225, 2005.
 
6) Takahashi K: A new concept of accommodation in ABO-incompatible kidney transplantation. Clinical Transplantation 19(Suppl 14):76-85, 2005.
 
P.75 掲載の参考文献
1) Chopek MW, Simmons RL, Platt JL: ABO-incompatible kidney transplantation; initial immunopathologic evaluation. Transplant Proc 19:4553, 1987.
 
2) Alexandre GP, Squifflet JP, De Bruyere M et al.: Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc 19:4538, 1987.
 
3) Sawada T, Fuchinoue S, Teraoka S: Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusion, splenectomy, and double-filtration plasmapheresis. Transplantation 74:1207-1210, 2002.
 
4) Sawada T, Fuchinoue S, Kawase T et al.: Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation. Clin Transplant 18:254-260, 2004.
PubMed
5) 甲斐耕太郎, 小山一郎, 関島光裕・他: 汎血球減少を 来し治療に難渋した血液型不適合生体腎移植の1例. 東女医大誌 75:26-31, 2005.
Medical*Online
6) Teraoka S, Sato S, Kai K et al.: Early steroid withdrawal protocol using basiliximab in kidney transplantation. Transplant Proc 36:478-482, 2004.
 
7) 中村正孝: CD25(IL-2Rα). 臨床免疫 34:443-448, 2000.
 
8) Golay J, Zaffaroni L, Vaccari T et al.: Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro:CD55 and CD59 regulate complement-mediated cell lysis. Blood 95:3900-3908, 2000.
PubMed
9) Chaiwatanatorn K, Lee N, Grigg A et al.: Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol 121:913-918, 2003.
PubMed
10) Tyden G, Kumlien G, Fehrman I: Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 76:730-731, 2003.
PubMed
11) Takahashi K: A new concept of accommodation in ABO-incompatible kidney transplantation. Clin Transplant 19:76-85, 2005.
 
P.78 掲載の参考文献
1) Sonnenday CJ, Warren D, Cooper M et al.: Plasmapheresis, CMV hyperimmuno globlin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 4:1315-1322, 2004.
 
2) Tyden G, Kumlien G, Genberg H et al.: ABO-incompatible kidney transplantations without splenectomy, using antigen-specific immnoabsorption and rituximab. Am J Transplant 5:145-148, 2005.
PubMed
3) Gloor JM, Lager DJ, Filder ME et al.: A comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 80:1572-1577, 2005.
 
4) Saito K, Nakagawa Y, Suma M et al.: Pinpoint targeted immnosuppression:anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy. Xenotransplantation 13(2):111-117, 2006.
 
5) 白川浩希, 石川英樹, 宮本直志・他: ABO血液型不適合生体腎移植における脾臓摘出術群と抗CD20抗体使用群の比較検討. 第42回日本移植学会総会臨時号: 2006, p281.
 
6) Mitsuhata N, Fujita R, Ito S et al.: Splenectomy and preoperative risks in ABO-incompatible kidney transplants. Transplantation 82:719-720, 2006.
PubMed
7) Becker YT, Samaniego-Picota M, Solinger HW: The emerging role of rituximab in organ transplantation. Transplant international 19:621-628, 2006.
 
8) Mitsuhata N, Fujita R, Ito S et al.: Is administration of rituximab at 375 mg/m2 without splenectomy appropriate for ABO-incompatible renal Transplant? Am J Transplant 5:3019, 2005.
 
9) Genberg H, Hansson A, Wemerson A et al.: Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 6(10):2418-2428, 2006.
PubMed
10) Mitsuhata N, Fujita R, Ito S et al.: ABO-incompatible renal transplantation without splenectomy between husband and wife among the ever oldest patients. Am J Transplant 6(12):3040-3041, 2006.
PubMed
P.84 掲載の参考文献
1) Katayama A, Kobayashi T, Uchlda K, Goto N, Matsuoka S et al.: Beneficial effect of antibody removal and enhanced immuno suppression flow cytometry cross match-positive and ABO incompatible renal transplantation. Transplantation Proceedings 34:2771-2772, 2002.
 
2) 片山昭男, 打田和治, 稲垣浩子, 佐藤哲彦, 渡邊出・他: ABO血液型不適合移植におけるミゾリビン併用維持免疫抑制療法. 今日の移植, 12:717-718, 1999.
 
3) 片山昭男: ABO血液型不適合腎移植における免疫抑制. 腎移植の最前線. (落合武徳・堀 誠司・編), 日本医学館, 東京, 2001, p110-115
 
4) 片山昭男, 打田和治, 稲垣浩子, 佐藤哲彦, 渡邊出・他: ABO血液型不適合腎移植の臨床成績と, 抗A, 抗B血液型抗体価測定法の比較検討. ABO血液型不適合移植の新戦略2001. 2001, p83-86.
 
5) 片山昭男, 打田和治, 後藤憲彦, 松岡慎, 佐藤哲彦・他: シクロフォスファミドを導入療法に用いたABO血液型不適合腎移植免疫抑制療法. ABO血液型不適合移植の新戦略2002. (高橋公太・田中紘一・編), 日本医学館, 東京, 2002, p22-27.
 
6) 片山昭男, 打田和治, 植木常雄, 後藤憲彦, 佐藤哲彦・他: ABO血液型不適合生体腎移植の液性拒絶反応に対する治療. ABO血液型不適合移植の新戦略2004 (高橋公太・田中紘一・編), 日本医学館, 東京, 2004, p59-61.
 
7) 片山昭男, 打田和治, 植木常雄, 後藤憲彦, 松岡慎・他: ABO血液型不適合腎移植におけるミゾリビン併用維持免疫療法と移植腎機能に関する検討. セラピューティック・リサーチ 25:32-34, 2004.
 
8) 片山昭男, 打田和治, 冨永芳博, 幅俊人, 松岡慎・他: 当センターにおける非血縁者間ABO血液型不適合生体腎移植症例. 今日の移植 18:98-100, 2005.
Medical*Online
9) 片山昭男, 打田和治, 冨永芳博, 長坂隆治, 松岡慎・他: ABO血液型不適合生体腎移植の免疫抑制療法-Cyclophosphamideを使用する当センターのレジメとその成績-. ABO血液型不適合移植の新戦略2006. (高橋公太・田中紘一・編), 日本医学館, 東京, 2006, p72-76.
 
10) Holtzman J, Bjerke T, Kane R: The effect of clinical pathways for renal transplant on patient outcomes and length of stay. Med Care 36:826-834, 1998.
PubMed
11) Darrikhuma IM:Development of a renal transplant clinical pathway:one hospital's journey. AACN Clin Issues 10:270-284, 1999.
 

書評

最近チェックした商品履歴

Loading...